Overcoming cancer drug resistance

Pipeline

Cancer drug resistance

INVESTORS

Interim Report Q2 2022

Conference call on CORIST

Tuesday October 4, 2022 at 10:00 am CET

PRESS RELEASES

30 September 2022

Scandion Oncology announce topline results from part 2 of the CORIST phase II trial

Data from part 2 of the trial confirm the safety and tolerability of SCO-101. The trial will continue with part 3 exploring an optimized dosing schedule, aiming to utilize the full potential of SCO-101 in this indication and combination.

Bo Rode Hansen is leaving the position as President and CEO of Scandion Oncology

Johnny Stilou, Chief Financial Officer at Scandion Oncology since July 2021, has been appointed acting CEO effective immediately. The process to identify a new permanent CEO has started.

Scandion Oncology announce change to its Executive Management

Maj Hedtjärn has decided to resign from her position as Chief Operating Officer and Head of R&D Operations. She will leave Scandion Oncology no later than December 31, 2022.

View all press releases

UPCOMING EVENTS

Conference call on CORIST

Our Executive Management will host a webcast and conference call.

Investor AW – Malmö

We will give a presentation and update on Scandion followed by a Q&A session.

Bio-Europe 2022

We will give a presentation and update on Scandion followed by a Q&A session.

View all upcoming events

Learn more about our unique first-in-class lead compound SCO-101

Read more about SCO-101

LATEST PRESENTATIONS

Redeye Transactions

Watch President & CEO Bo Rode Hansen’s presentation from Redeye Transactions

Aktiespararna

Watch Chief Operating Officer Maj Hedtjärn present Scandion at Aktiespararna Småbolagsdagarna 2022

DAF Interview

Watch President and CEO Bo Rode Hansen present Scandion to The Danish Shareholder Association

View all presentations

INVESTOR

Scandion Oncology Capital Markets Day

September 8, 2021

Watch the presentations from Scandion Oncology’s Capital Markets Day

Capital Markets Day View all presentations

CAREER

A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments